AU2012352168C1 - Composition and method for the diagnosis and treatment of iron-related disorders - Google Patents

Composition and method for the diagnosis and treatment of iron-related disorders Download PDF

Info

Publication number
AU2012352168C1
AU2012352168C1 AU2012352168A AU2012352168A AU2012352168C1 AU 2012352168 C1 AU2012352168 C1 AU 2012352168C1 AU 2012352168 A AU2012352168 A AU 2012352168A AU 2012352168 A AU2012352168 A AU 2012352168A AU 2012352168 C1 AU2012352168 C1 AU 2012352168C1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
rgmc
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2012352168A
Other languages
English (en)
Other versions
AU2012352168A1 (en
AU2012352168B2 (en
Inventor
Bernhard Mueller
Jennifer M. Perez
Andreas Popp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Original Assignee
AbbVie Deutschland GmbH and Co KG
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG, AbbVie Inc filed Critical AbbVie Deutschland GmbH and Co KG
Publication of AU2012352168A1 publication Critical patent/AU2012352168A1/en
Application granted granted Critical
Publication of AU2012352168B2 publication Critical patent/AU2012352168B2/en
Priority to AU2017235976A priority Critical patent/AU2017235976B2/en
Publication of AU2012352168C1 publication Critical patent/AU2012352168C1/en
Priority to AU2019261820A priority patent/AU2019261820B2/en
Priority to AU2022200452A priority patent/AU2022200452B2/en
Priority to AU2025208470A priority patent/AU2025208470A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2012352168A 2011-12-14 2012-12-13 Composition and method for the diagnosis and treatment of iron-related disorders Active AU2012352168C1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2017235976A AU2017235976B2 (en) 2011-12-14 2017-09-28 Composition and method for the diagnosis and treatment of iron-related disorders
AU2019261820A AU2019261820B2 (en) 2011-12-14 2019-11-08 Composition and method for the diagnosis and treatment of iron-related disorders
AU2022200452A AU2022200452B2 (en) 2011-12-14 2022-01-24 Composition and method for the diagnosis and treatment of iron-related disorders
AU2025208470A AU2025208470A1 (en) 2011-12-14 2025-07-24 Composition and method for the diagnosis and treatment of iron-related disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161570715P 2011-12-14 2011-12-14
US61/570,715 2011-12-14
PCT/US2012/069586 WO2013090635A2 (en) 2011-12-14 2012-12-13 Composition and method for the diagnosis and treatment of iron-related disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017235976A Division AU2017235976B2 (en) 2011-12-14 2017-09-28 Composition and method for the diagnosis and treatment of iron-related disorders

Publications (3)

Publication Number Publication Date
AU2012352168A1 AU2012352168A1 (en) 2014-05-01
AU2012352168B2 AU2012352168B2 (en) 2017-06-29
AU2012352168C1 true AU2012352168C1 (en) 2018-01-25

Family

ID=47436267

Family Applications (5)

Application Number Title Priority Date Filing Date
AU2012352168A Active AU2012352168C1 (en) 2011-12-14 2012-12-13 Composition and method for the diagnosis and treatment of iron-related disorders
AU2017235976A Expired - Fee Related AU2017235976B2 (en) 2011-12-14 2017-09-28 Composition and method for the diagnosis and treatment of iron-related disorders
AU2019261820A Active AU2019261820B2 (en) 2011-12-14 2019-11-08 Composition and method for the diagnosis and treatment of iron-related disorders
AU2022200452A Active AU2022200452B2 (en) 2011-12-14 2022-01-24 Composition and method for the diagnosis and treatment of iron-related disorders
AU2025208470A Pending AU2025208470A1 (en) 2011-12-14 2025-07-24 Composition and method for the diagnosis and treatment of iron-related disorders

Family Applications After (4)

Application Number Title Priority Date Filing Date
AU2017235976A Expired - Fee Related AU2017235976B2 (en) 2011-12-14 2017-09-28 Composition and method for the diagnosis and treatment of iron-related disorders
AU2019261820A Active AU2019261820B2 (en) 2011-12-14 2019-11-08 Composition and method for the diagnosis and treatment of iron-related disorders
AU2022200452A Active AU2022200452B2 (en) 2011-12-14 2022-01-24 Composition and method for the diagnosis and treatment of iron-related disorders
AU2025208470A Pending AU2025208470A1 (en) 2011-12-14 2025-07-24 Composition and method for the diagnosis and treatment of iron-related disorders

Country Status (8)

Country Link
US (5) US10118958B2 (enExample)
EP (2) EP2791173B1 (enExample)
JP (6) JP6342812B2 (enExample)
CN (2) CN104144947B (enExample)
AU (5) AU2012352168C1 (enExample)
CA (2) CA3204283A1 (enExample)
MX (2) MX357708B (enExample)
WO (1) WO2013090635A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013090635A2 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
US20150164991A1 (en) * 2013-11-01 2015-06-18 Vanderbilt University Method and Kit for Evaluating and Monitoring a Treatment Program for Anemia
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
JP6497760B2 (ja) * 2015-04-28 2019-04-10 田辺三菱製薬株式会社 ＲＧＭａ結合タンパク質及びその使用
CA3117561A1 (en) * 2018-10-23 2020-04-30 Samantha NICHOLLS Rgmc-selective inhibitors and use thereof
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
WO2021062171A1 (en) * 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
JP7583401B2 (ja) 2020-04-13 2024-11-14 国立大学法人大阪大学 血液分析装置
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
AU2021273014A1 (en) * 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
CA3235096A1 (en) * 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease

Family Cites Families (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526A (en) 1846-05-16 Improvement in the mode o
US938A (en) 1838-09-22 Improvement in paddle-wheels for propelling boats
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
ATE37983T1 (de) 1982-04-22 1988-11-15 Ici Plc Mittel mit verzoegerter freigabe.
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
WO1986005803A1 (fr) 1985-03-30 1986-10-09 Marc Ballivet Procede d'obtention d'adn, arn, peptides, polypeptides ou proteines, par une technique de recombinaison d'adn
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5635600A (en) 1986-07-07 1997-06-03 Trustees Of Dartmouth College Bifunctional and heteroantibodies specific for the high affinity Fc receptor for immunoglobulin G on human mononuclear phagocytes
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0273115B1 (en) 1986-10-22 1994-09-07 Abbott Laboratories Chemiluminescent acridinium and phenanthridinium salts
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1997891A1 (en) 1988-09-02 2008-12-03 Dyax Corporation Generation and selection of recombinant varied binding proteins
US5241070A (en) 1988-09-26 1993-08-31 Ciba Corning Diagnostics Corp. Nucleophilic polysubstituted aryl acridinium esters and uses thereof
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU665190B2 (en) 1990-07-10 1995-12-21 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992002551A1 (en) 1990-08-02 1992-02-20 B.R. Centre Limited Methods for the production of proteins with a desired function
US5135875A (en) 1990-08-15 1992-08-04 Abbott Laboratories Protein precipitation reagent
CA2048302A1 (en) 1990-08-15 1992-02-16 Victoria P. Meucci Solubilization reagent for biological test samples
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ATE439435T1 (de) 1991-03-01 2009-08-15 Dyax Corp Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon
DE69233750D1 (de) 1991-04-10 2009-01-02 Scripps Research Inst Bibliotheken heterodimerer Rezeptoren mittels Phagemiden
ATE177841T1 (de) 1991-04-10 1999-04-15 Biosite Diagnostics Inc ''crosstalk''- oder übersprech-inhibitoren und ihre verwendung
EP0579767B1 (en) 1991-04-11 2000-08-23 Biosite Diagnostics Inc. Novel conjugates and assays for simultaneous detection of multiple ligands
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
CA2069530A1 (en) 1991-06-03 1992-12-04 Cass J. Grandone Reagent pack for immunoassays
WO1992022324A1 (en) 1991-06-14 1992-12-23 Xoma Corporation Microbially-produced antibody fragments and their conjugates
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993020442A1 (en) 1992-03-30 1993-10-14 Abbott Laboratories Reagents and methods for the detection and quantification of thyroxine in fluid samples
US5352803A (en) 1992-03-30 1994-10-04 Abbott Laboratories 5(6)-methyl substituted fluorescein derivatives
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DK1231268T3 (da) 1994-01-31 2005-11-21 Univ Boston Polyklonale antistofbiblioteker
PT749325E (pt) 1994-03-07 2002-11-29 Medarex Inc Mpleculas biespecificas possuindo utilidades clinicas
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US6111166A (en) 1994-09-19 2000-08-29 Medarex, Incorporated Transgenic mice expressing human Fcα and β receptors
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
JPH11503914A (ja) 1995-04-21 1999-04-06 セル ジェネシス，インコーポレイテッド 大ゲノムｄｎａ欠失の生成
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
US6127977A (en) 1996-11-08 2000-10-03 Cohen; Nathan Microstrip patch antenna with fractal structure
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6017517A (en) 1996-12-18 2000-01-25 The Dial Corporation Method for treating human nails
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
PT971946E (pt) 1997-01-21 2006-11-30 Gen Hospital Corp Selecção de proteínas utilizando fusões arn-proteína
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
WO1999028349A2 (en) 1997-12-02 1999-06-10 Medarex, Inc. CELLS EXPRESSING ANTI-Fc RECEPTOR BINDING COMPONENTS
JP2002505097A (ja) 1998-03-03 2002-02-19 アブジェニックス インク． 治療薬としてのｃｄ１４７結合分子
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CA2336139C (en) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Large porous particles emitted from an inhaler
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
JP2002530081A (ja) 1998-11-18 2002-09-17 ジェネンテック・インコーポレーテッド 親抗体より高度な結合親和性を持つ抗体変異体
WO2000037504A2 (en) 1998-12-23 2000-06-29 Pfizer Inc. Human monoclonal antibodies to ctla-4
US6231768B1 (en) 1999-01-19 2001-05-15 Nalco Chemical Company Rheology modification of settled solids in mineral processing
AU3921600A (en) * 1999-03-25 2000-10-09 Abbott Gmbh & Co. Kg Human antibodies that bind human il-12 and methods for producing
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
CA2399148A1 (en) 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
EP2386575A3 (en) 2000-06-29 2011-11-30 Abbott Laboratories Dual specificity antibodies and methods of making and using
KR101054732B1 (ko) 2000-07-18 2011-08-05 더 유나이티드 스테이츠 오브 아메리카 애즈 리프리젠티드 바이 더 세크레터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 생물학적 데이터의 숨겨진 패턴에 근거한 생물학적 상태의 식별 방법
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US6890763B2 (en) 2001-04-30 2005-05-10 Syn X Pharma, Inc. Biopolymer marker indicative of disease state having a molecular weight of 1350 daltons
ES2405551T3 (es) 2001-10-01 2013-05-31 Dyax Corporation Vectores de presentación eucariotas multicatenarios y usos de los mismos
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
AU2003239409A1 (en) 2002-05-09 2003-11-11 Surromed, Inc. Methods for time-alignment of liquid chromatography-mass spectrometry data
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
CA2517145C (en) 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7968091B2 (en) 2005-02-16 2011-06-28 The General Hospital Corporation Methods and compositions to regulate iron metabolism
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
US7906293B2 (en) 2007-04-09 2011-03-15 Abbott Laboratories Acridinium phenyl esters useful in the analysis of biological
EP2033971A1 (de) * 2007-09-06 2009-03-11 Abbott GmbH & Co. KG Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
NZ588587A (en) 2008-03-19 2013-01-25 China Synthetic Rubber Corp Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
EP2349332B1 (en) 2008-11-13 2019-10-23 The General Hospital Corporation Methods and compositions for regulating iron homeostasis by modulation bmp-6
US20110293526A1 (en) 2008-11-20 2011-12-01 University Of Southern California Compositions and methods to modulate hair growth
CN105388293A (zh) 2008-12-31 2016-03-09 雅培医护站股份有限公司 用于使用核苷酸缀合物的免疫测定的方法和设备
KR20120118002A (ko) * 2009-12-08 2012-10-25 애보트 게엠베하 운트 콤파니 카게 망막 신경 섬유 층 변성의 치료에 사용하기 위한 ｒｇｍ ａ 단백질에 대한 모노클로날 항체
EP2665752B1 (en) 2011-01-19 2018-10-10 Ferrumax Pharmaceuticals, Inc. Compositions for regulating iron homeostasis and methods of using same
WO2013090635A2 (en) * 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
WO2021062171A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. Methods for treating anemia of chronic disease
KR20220088699A (ko) 2019-09-27 2022-06-28 디스크 메디슨, 인크. 골수섬유증 및 관련 상태의 치료 방법
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
CA3235096A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease

Also Published As

Publication number Publication date
AU2012352168A1 (en) 2014-05-01
CA3204283A1 (en) 2013-06-20
AU2019261820B2 (en) 2021-10-28
MX2014007177A (es) 2014-10-17
JP2018148908A (ja) 2018-09-27
US12098189B2 (en) 2024-09-24
MX2018008882A (es) 2021-06-15
JP2015502753A (ja) 2015-01-29
US20240262901A1 (en) 2024-08-08
CN104144947A (zh) 2014-11-12
US10822403B2 (en) 2020-11-03
BR112014013656A2 (pt) 2020-10-27
EP2791173A2 (en) 2014-10-22
JP6342812B2 (ja) 2018-06-13
CN107459576A (zh) 2017-12-12
MX357708B (es) 2018-07-20
JP6926176B2 (ja) 2021-08-25
US20210155681A1 (en) 2021-05-27
AU2022200452A1 (en) 2022-02-17
US20250179159A1 (en) 2025-06-05
JP7238042B2 (ja) 2023-03-13
CN104144947B (zh) 2017-10-27
WO2013090635A3 (en) 2013-09-26
US12098192B2 (en) 2024-09-24
AU2012352168B2 (en) 2017-06-29
WO2013090635A2 (en) 2013-06-20
JP2020058359A (ja) 2020-04-16
JP2023078174A (ja) 2023-06-06
US20130330343A1 (en) 2013-12-12
US20190292244A1 (en) 2019-09-26
EP2791173B1 (en) 2020-07-29
AU2017235976A1 (en) 2017-10-19
JP7597842B2 (ja) 2024-12-10
EP3800200A1 (en) 2021-04-07
CA2855840A1 (en) 2013-06-20
AU2017235976B2 (en) 2019-08-22
CA2855840C (en) 2023-08-29
AU2025208470A1 (en) 2025-08-14
US10118958B2 (en) 2018-11-06
JP2025028985A (ja) 2025-03-05
AU2022200452B2 (en) 2025-05-08
JP2021191267A (ja) 2021-12-16
AU2019261820A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
US12098192B2 (en) Composition and method for the diagnosis and treatment of iron-related disorders
JP6336397B2 (ja) 鉄関連障害を診断および治療するための組成物および方法
BR112014013656B1 (pt) Anticorpo monoclonal isolado anti-rgmc, uso do mesmo para o tratamento de uma doença do metabolismo do ferro, bem como composição farmacêutica, kit e método para determinar presença, quantidade ou concentração de rgmc em amostras

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 OCT 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 05 OCT 2017

FGA Letters patent sealed or granted (standard patent)